Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 5/20 | 0.44 |
| ▸ | SLC34A2 | O95436 | 5/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CCR5 | P51681 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.38 |
| ▸ | SLC34A3 | Q8N130 | 1/20 | 0.38 |
| ▸ | SLC20A1 | Q8WUM9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL265724 | 1.00 | ACKR3 (0.44) | ACKR3SLC34A2KDRTDP1CCR5 | |
| SCHEMBL274290 | 0.93 | MEN1 (0.42) | ACKR3SLC34A2TDP1SIGMAR1 | |
| SCHEMBL265952 | 0.93 | MEN1 (0.42) | ACKR3SLC34A2TDP1SIGMAR1 | |
| SCHEMBL274045 | 0.92 | SLC34A2 (0.47) | ACKR3SLC34A2SLC34A1SLC34A3SLC20A1 | |
| SCHEMBL267900 | 0.92 | SLC34A2 (0.47) | ACKR3SLC34A2SLC34A1SLC34A3SLC20A1 | |
| SCHEMBL268140 | 0.92 | ACKR3 (0.45) | ACKR3SLC34A2TDP1SIGMAR1SLC34A1 | |
| SCHEMBL273680 | 0.92 | ACKR3 (0.45) | ACKR3SLC34A2TDP1SIGMAR1SLC34A1 | |
| SCHEMBL273682 | 0.91 | NPC1 (0.44) | SLC34A2TDP1SIGMAR1SLC34A1SLC34A3 | |
| SCHEMBL267724 | 0.91 | NPC1 (0.44) | SLC34A2TDP1SIGMAR1SLC34A1SLC34A3 | |
| SCHEMBL268571 | 0.91 | MEN1 (0.42) | SLC34A2TDP1SIGMAR1SLC34A1SLC34A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120115851-A1 | COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-05-10 | — | — | US | disclosed |
| US-20120115851-A1 | COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-05-10 | — | — | US | disclosed |
| US-8134015-B2 | Compound inhibiting in vivo phosphorous transport and medicine containing the same | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-03-13 | — | — | US | disclosed |
| US-8134015-B2 | Compound inhibiting in vivo phosphorous transport and medicine containing the same | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2012-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115851-A1 | COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME | SLC34A1, SLC34A2, SLC20A2 | ACKR3 809/4885SLC34A2 2/4885KDR 1104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.